PPAR modulators and PPAR pan agonists for metabolic diseases: The next generation of drugs targeting peroxisome proliferator-activated receptors?

Current Topics in Medicinal Chemistry

Volumn 8, Issue 9, 2008, Pages 728-749

  Feldman, P L ^a   Lambert, M H ^a   Henke, B R ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Coregulator; Diabetes; Metabolic disease; PPAR modulator; PPAR pan agonist; PPAR ; SPPARM

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; CLOFIBRATE; FARGLITAZAR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GW 584148; GW 677954; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METAGLIDASEN; METFORMIN; MURAGLITAZAR; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR PAN AGONIST; PIOGLITAZONE; PLACEBO; PPM 204; RAGAGLITAZAR; ROSIGLITAZONE; SELECTIVE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TELMISARTAN; TESAGLITAZAR; UNINDEXED DRUG;

ADJUVANT THERAPY; AREA UNDER THE CURVE; BONE DENSITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DYSLIPIDEMIA; FLUID RETENTION; HEART WEIGHT; HEMODILUTION; HUMAN; HYPERLIPIDEMIA; LIGAND BINDING; METABOLIC DISORDER; MONOTHERAPY; MUSCLE WEAKNESS; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL EDEMA; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; WEIGHT GAIN;

DRUG DELIVERY SYSTEMS; DRUG TOXICITY; HUMANS; METABOLIC DISEASES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN BINDING;

EID: 47249146946     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608784535084     Document Type: Review

References (116)

1. Staels, B.; Fruchart, J.-C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005, 54, 2460-2470.
2. Berger, J. P.; Akiyama, T. E.; Meinke, P. T. PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 2005, 26, 244-251.
3. Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999, 20, 649-688.
4. Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R. The PPARs: From orphan receptors to drug discovery. J. Med. Chem. 2000, 43, 527-550.
5. Feige, J. N.; Gelman, L.; Michalik, L.; Desvergne, B.; Wahli, W. From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res. 2006, 45, 120-159.
6. Evans, R. M.; Barish, G. D.; Wang, Y.-X. PPARs and the complex journey to obesity. Nat. Med. 2004, 10, 355-361.
7. Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347, 645-650.
8. Lehmann, J. M.; Moore, L. B.; Simth-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 1995, 270, 12953-12956.
9. Mudaliar, S.; Henry, R. R. PPAR agonists in health and disease: A pathophysiologic and clinical overview. Curr. Opin. Endocrinol. Diabetes 2002, 9, 285-302.
10. Lee, C.-H.; Olson, P.; Hevener, A.; Mehl, I.; Chong, L.-W.; Olefsky, J. M.; Gonzalez, F. J.; Ham, J.; Kang, H.; Peters, J. M.; Evans, R. M. PPARδ regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. USA 2006, 103, 3444-3449.
11. Oliver, W. R., Jr.; Shenk, J. L.; Snaith, M. R.; Russell, C. S.; Plunket, K. D.; Bodkin, N. L.; Lewis, M. C.; Winegar, D. A.; Sznaidman, M. L.; Lambert, M. H.; Xu, H. E.; Sternbach, D. D.; Kliewer, S. A.; Hansen, B. C.; Willson, T. M. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA 2001, 98, 5306-5311.
12. Henke, B. R. Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists for the Treatment of Type 2 Diabetes. J. Med. Chem. 2004, 47, 4118-4127.
13. Rubenstrunk, A.; Hanf, R.; Hum, D. W.; Fruchart, J.-C.; Staels, B. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2007, 1771, 1065-1081.
14. Graham, D. J.; Staffa, J. A.; Shatin, D.; Andrade, S. E.; Schech, S. D.; La Grenade, L.; Gurwitz, J. H.; Chan, K. A.; Goodman, M. J.; Platt, R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lolwering drugs. JAMA 2004, 292, 2585-2590.
15. Shek, A.; Ferrill, M. J. Statin-fibrate combination therapy. Ann. Pharmacother. 2001, 35, 908-917.
16. Tonstad, S.; Retterstol, K.; Ose, L.; Oehman, K. P.; Lindberg, M. B.; Svensson, M. The dual peroxisome proliferator-activated receptor α/ γ agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin. Metab. Clin. Exp. 2007, 56, 1285-1292.
17. Nakamura, T.; Funahashi, T.; Yamashita, S.; Nishida, M.; Nishida, Y.; Takahashi, M.; Hotta, K.; Kuriyama, H.; Kihara, S.; Ohuchi, N.; Nishimura, T.; Kishino, B.-i.; Ishikawa, K.; Kawamoto, T.; Tokunaga, K.; Nakagawa, C.; Mineo, I.; Watanabe, F.; Tarui, S.; Matsuzawa, Y. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation-double-blind placebo-controlled trial. Diabetes Res. Clin. Pract. 2001, 54, 181-190.
18. Mudaliar, S.; Chang, A. R.; Henry, R. R. Thiazolidinediones, peripheral edema, and type 2 diabetes: Incidence, pathophysiology, and clinical implications. Endocr. Pract. 2003, 9, 406-416.
19. Guan, Y.; Hao, C.; Cha, D. R.; Rao, R.; Lu, W.; Kohan, D. E.; Magnuson, M. A.; Redha, R.; Zhang, Y.; Breyer, M. D. Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat. Med. 2005, 11, 861-866.
20. Chen, L.; Yang, B.; McNulty, J. A.; Clifton, L. G.; Diaz, J. G.; Grimes, A. M.; Strum, J. C.; Harrington, W. W.; Chen, Z.; Balon, T. W.; Stimpson, S. A.; Brown, K. K. GI262570, a peroxisome proliferator-activated receptor γ agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J. Pharmacol. Exp. Ther. 2005, 312, 718-725.
21. Hong, G.; Lockhart, A.; Davis, B.; Rahmoune, H.; Baker, S.; Ye, L.; Thompson, P.; Shou, Y.; O'Shaughnessy, K.; Ronco, P.; Brown, J. PPARγ activation enhances cell surface ENaC via up-regulation of SGK1 in human collecting duct cells. FASEB J. 2003, 17, 1966-1968.
22. Chang, F.; Jaber, L. A.; Berlie, H. D.; O'Connell, M. B. Evolution of peroxisome proliferator-activated receptor agonists. Ann. Pharmacother. 2007, 41, 973-983.
23. Nissen, S. E.; Woslki, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356, 2457-2471.
24. Diamond, G. A.; Bax, L.; Kaul, S., Uncertain effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death. Ann. Internal Med. 2007, 147, 578-582.
25. Home, P. D.; Phil, D.; Pocock, S. J.; Beck-Nielsen, H.; Gomis, R.; Hanefeld, M.; Jones, N. P.; Komajda, M.; McMurray, J. J. V.; Campbell, I., et. al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N. Engl. J. Med. 2007, 357, 28-38.
26. Ali, A. A.; Weinstein, R. S.; Stewart, S. A.; Parfitt, A. M.; Manolagas, S. C.; Jilka, R. L. Rosightazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005, 146, 1226-1235.
27. Rzonca, S. O.; Suva, L. J.; Gaddy, D.; Montague, D. C.; Lecka-Czernik, B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145, 401-406.
28. Grey, A.; Bolland, M.; Gamble, G.; Wattie, D.; Horne, A.; Davidson, J.; Reid, I. R. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: A randomized, controlled trial. J. Clin. Endocrinol. Metab. 2007, 92, 1305-1310.
29. Kahn, S. E.; Haffner, S. M.; Heise, M. A.; Herman, W. H.; Holman, R. R.; Jones, N. P.; Kravitz, B. G.; Lachin, J. M.; O'Neill, C.; Zinman, B.; Viberti, G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006, 355, 2427-2443.
30. Schwartz, A. V.; Sellmeyer, D. E. Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes. Expert Opin. Drug Safety 2008, 7, 69-78.
31. Vestergaard, P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporosis Int. 2007, 18, 427-444.
32. Sertznig, P.; Seifert, M.; Tilgen, W.; Reichrath, J. Present concepts and future outlook: Function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. Cell. Physiol. 2007, 212, 1-12.
33. Rumi, M. A. K.; Ishihara, S.; Kazumori, H.; Kadowaki, Y.; Kinoshita, Y. Can PPARγ ligands be used in cancer therapy? Curr. Med. Chem.: Anti-Cancer Agents, 2004, 4, 465-477.
34. Wilson, T. M.; Lehmann, J. M.; Kliewer, S. A. Discovery of ligands for the nuclear peroxisome proliferator-activated receptors. Ann. N. Y. Acad. Sci. 1996, 804, 276-283.
35. Yu, S.; Reddy, J. K. Transcription coactivators for peroxisome proliferator-activated receptors. Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2007, 1771, 936-951.
36. Powell, E.; Kuhn, P.; Xu, W. Nuclear receptor cofactors in PPARγ-mediated adipogemis and adipocyte energy metabolism. PPAR Res. 2007, No pp. given.
37. Perissi, V.; Rosenfeld, M. G. Controlling nuclear receptors: The circular logic of cofactor cycles. Nat. Rev. Mol. Cell Biol. 2005, 6, 542-554.
38. Evans, J. L.; Lin, J. J.; Goldfine, I. D. Novel approach to treat insulin resistance, type 2 diabetes and the metabolic syndrome: simultaneous activation of PPARα, PPARγ, and PPARδ. Curr. Diabetes Rev. 2005, 1, 299-307.
39. Delarue, J.; Le Guen, V.; Allain, G.; Corporeau, C.; Guillerm, S. Can marine omega 3 fatty acids prevent and/or treat metabolic syndrome? Curr. Nutr. Food Sci. 2007, 3, 151-156.
40. Carpentier, Y. A.; Portois, L.; Malaisse, W. J. n-3 fatty acids and the metabolic syndrome. Am. J. Clin. Nutr. 2006, 83, 1499S-1504S.
41. Bordoni, A.; Di Nunzio, M.; Danesi, F.; Biagi, P. L., Polyunsaturated fatty acids: From diet to binding to PPARs and other nuclear receptors. Genes Nutr. 2006, 1, 95-106.
42. Grundy, S. M.; Hansen, B.; Smith, S. C., Jr.; Cleeman, J. I.; Kahn, R. A. Clinical management of metabolic syndrome: Report of the American Heart Association National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004, 109, 551-556.
43. Grundy, S. M.; Brewer, H. B., Jr.; Cleeman, J. I.; Smith, S. C., Jr.; Lenfant, C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109, 433-438.
44. Henke, B. R.; Blanchard, S.G.; Brackeen, M. F.; Brown, K. K.; Cobb, J. E.; Collins, J. L.; Harrington, W. W., Jr.; Hashim, M. A.; Hull-Ryde, E. A.; Kaldor, I.; Kliewer, S. A.; Lake, D. H.; Leesnitzer, L. M.; Lehmann, J. M.; Lenhard, J. M.; Orband-Miller, L. A.; Miller, J. F.; Mook, R. A.; Noble, S. A.; Oliver, W.; Parks, D. J.; Plunket, K. D.; Szewczyk, J. R., Willson, T. M. N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents. J. Med. Chem. 1998, 41, 5020-5036.
45. Cobb, J. E.; Blanchard, S. G.; Boswell, E. G.; Brown, K. K.; Charifson, P. S.; Cooper, J. P.; Collins, J. L.; Dezube, M.; Henke, B. R.; Hull-Ryde, E. A.; Lake, D. H.; Lenhard, J. M.; Oliver, W., Jr.; Oplinger, J.; Pentti, M.; Parks, D. J.; Plunket, K. D.; Tong, W.-Q. N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent. J. Med. Chem. 1998, 41, 5055-5069
46. Collins, J. L.; Blanchard, S. G.; Boswell, G. E.; Charifson, P. S.; Cobb, J. E.; Henke, B. R.; Hull-Ryde, E. A.; Kazmierski, W. M.; Lake, D. H.; Leesnitzer, L. M.; Lehmann, J.; Lenhard, J. M.; Orband-Miller, L. A.; Gray-Nunez, Y.; Parks, D. J.; Plunkett, K. D.; Tong, W.-Q. N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists. 2. Structure-Activity Relationship and Optimization of the Phenyl Alkyl Ether Moiety. J. Med. Chem. 1998, 41, 5037- 054.
47. Sznaidman, M. L.; Haffner, C. D.; Maloney, P. R.; Fivush, A.; Chao, E.; Goreham, D.; Sierra, M. L.; LeGrumelec, C.; Xu, H. E.; Montana, V. G.; Lambert, M. H.; Willson, T. M.; Oliver, W. R.; Sternbach, D. D. Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ) - synthesis and biological activity. Bioorg. Med. Chem. Leutt. 2003, 13, 1517-1521.
48. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 1998, 395, 137-143.
49. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Parks, D. J.; Blanchard, S. G.; Brown, P. J.; Sternbach, D. D.; Lehmann, J. M.; Wisely, G. B.; Willson, T. M.; Kliewer, S. A.; Milburn, M. V. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 1999, 3, 397-403.
50. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; Collins, J. L.; Oplinger, J. A.; Kliewer, S. A.; Gampe, R. T., Jr.; McKee, D. D.; Moore, J. T.; Willson, T. M. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA 2001, 98, 13919-13924.
51. Hansen, B. C.; Tigno, X. T. The rhesus monkey (Macaca mulatta) manifests all features of human type 2 diabetes, Animal Models of Diabetes (2nd Edition), 2007, 251-270.
52. Jones, A. B. Peroxisome proliferator-activated receptor (PPAR) modulators: Diabetes and beyond. Med. Res. Rev. 2001, 21, 540-552.
53. Adams, A. D.; Yuen, W.; Hu, Z.; Santini, C.; Jones, A. B.; MacNaul, K. L.; Berger, J. P.; Doebber, T. W.; Moller, D. E. Amphipathic 3-Phenyl-7-propylbenzisoxazoles; human PPAR γ, δ and α agonists. Bioorg. Med. Chem. Lett. 2003, 13, 931-935.
54. Santini, C.; Berger, G. D.; Han, W.; Mosley, R.; MacNaul, K.; Berger, J.; Doebber, T.; Wu, M.; Moller, D. E.; Tolman, R. L.; Sahoo, S. P. Phenylacetic acid derivatives as hPPAR agonists. Bioorg. Med. Chem. Lett. 2003, 13, 1277-1280.
55. Mogensen, J. P.; Jeppesen, L.; Bury, P. S.; Pettersson, I.; Fleckner, J.; Nehlin, J.; Frederiksen, K. S.; Albrektsen, T.; Din, N.; Mortensen, S. B.; Svensson, L. A.; Wassermann, K.; Wulff, E. M.; Ynddal, L.; Sauerberg, P. Design and synthesis of novel PPARα/γ/δ triple activators using a known PPARα/γ dual activator as structural template. Bioorg. Med. Chem. Lett. 2003, 13, 257-260.
56. Cantin, L.-D.; Liang, S.; Ogutu, H.; Iwuagwu, C. I.; Boakye, K.; Bullock, W. H.; Burns, M.; Clark, R.; Claus, T.; dela Cruz, F. E.; Daly, M.; Ehrgott, F. J.; Johnson, J. S.; Keiper, C.; Livingston, J. N.; Schoenleber, R. W.; Shapiro, J.; Town, C.; Yang, L.; Tsutsumi, M.; Ma, X. Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups - new classes of PPAR γ/δ and PPAR α/γ/δ agonists. Bioorg. Med. Chem. Lett. 2007, 17, 1056-1061.
57. Rudolph, J.; Chen, L.; Majumdar, D.; Bullock, W. H.; Burns, M.; Claus, T.; Dela Cruz, F. E.; Daly, M.; Ehrgott, F. J.; Johnson, J. S.; Livingston, J. N.; Schoenleber, R. W.; Shapiro, J.; Yang, L.; Tsutsumi, M.; Ma, X. Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR α/γ/δ pan agonists: Synthesis, structure-activity relationship, and in vivo efficacy. J. Med. Chem. 2007, 50, 984-1000.
58. Mahindroo, N.; Peng, Y.-H.; Lin, C.-H.; Tan, U.-K.; Prakash, E.; Lien, T.-W.; Lu, I.-L.; Lee, H.-J.; Hsu, J. T.-A.; Chen, X.; Liao, C.-C.; Lyu, P.-C.; Chao, Y.-S.; Wu, S.-Y.; Hsieh, H.-P. Structural Basis for the Structure-Activity Relationships of Peroxisome Proliferator-Activated Receptor Agonists. J. Med. Chem. 2006, 49, 6421-6424.
59. Mahindroo, N.; Wang, C.-C.; Liao, C.-C.; Huang, C.-F.; Lu, I.-L.; Lien, T.-W.; Peng, Y.-H.; Huang, W.-J.; Lin, Y.-T.; Hsu, M.-C.; Lin, C.-H.; Tsai, C.-H.; Hsu, J. T. A.; Chen, X.; Lyu, P.-C.; Chao, Y.-S.; Wu, S.-Y.; Hsieh, H.-P. Indol-1-yl Acetic Acids as Peroxisome Proliferator-Activated Receptor Agonists: Design, Synthesis, Structural Biology, and Molecular Docking Studies. J. Med. Chem. 2006, 49, 1212-1216.
60. Mahindroo, N.; Huang, C.-F.; Peng, Y,-H.; Wang, C.-C.; Liao, C.-C.; Lien, T.-W.; Chittimalla, S. K.; Huang, W.-J.; Chai, C.-H.; Prakash, E.; Chen, C.-P.; Hsu, T.-A.; Peng, C.-H.; Lu, I.-L.; Lee, L.-H.; Chang, Y.-W.; Chen, W.-C.; Chou, Y.-C.; Chen, C.-T.; Goparaju, C. M. V.; Chen, Y.-S.; Lan, S.-J.; Yu, M.-C.; Chen, X.; Chao, Y.-S.; Wu, S.-Y.; Hsieh, H.-P. Novel Indole-Based Peroxisome Proliferator-Activated Receptor Agonists: Design, SAR, Structural Biology, and Biological Activities. J. Med. Chem. 2005, 48, 8194-8208.
61. Henke, B. R.; Heyer, D. Recent advances in estrogen receptor modulators. Curr. Opin. Drug Discovery Dev. 2005, 8, 437-448
62. Jordan, V. C. Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions. J. Med. Chem. 2003, 46, 883-908.
63. Jordan, V. C. Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents. J. Med. Chem. 2003, 46, 1081-1111.
64. Brzozowski, A. M.; Pike, A. C. W., Dauter, Z., Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafsson, J.- A.; Carlquist, M. Molecular basis of agonism and antagonism in the estrogen receptor. Nature 1997, 389, 753-758.
65. Xu, H. E.; Stanley, T. B.; Montano, V. G.; Lambert, M. H.; Shearer, B. G.; Cobb, J. E.; McKee, D. O.; Galardi, C. M.; Plunket, K. D.; Nolte, R. T.; Parks, D. J.; Moore, J. T.; Kilewer, S. A.; Willson, T. M.; Stimmel, J. B. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα. Nature 2002, 415, 813-817.
66. Einstein, M.; Akiyama, T. E.; Castriota, G. A.; Wang, C. F.; McKeever, B.; Mosley, R. T.; Becker, J. W.; Moller, D. E.; Meinke, P. T.; Wood. H. B.; Berger, J. P. The differential interactions of peroxisome proliferator-activated receptor γ ligands with Tyr473 is a physical basis for their unique biological activities. Mol. Pharmacol. 2008, 73, 62-74.
67. Burgermeister, E.; Schnoebelen, A.; Flament, A.; Benz, J.; Stihle, M.; Gsell, B.; Rufer, A.; Ruf, A.; Kuhn, B.; Marki, H. P.; Mizrahi, J.; Sebokova, E.; Niesor, E.; Meyer, M. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1α, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol. Endocrinol. 2006, 20, 809-830.
68. Lu, I.-L.; Huang, C.-F.; Peng, Y.-H.; Lin, Y.-T.; Hsieh, H.-P.; Chen, C.-T.; Lien, T.-W.; Lee, H.-J.;, Mahindroo, N.; Prakash, E.; Yueh, A.; Chen, H.-Y.; Goparaju, C. M. V.; Chen, X.; Liao, C.-C.; Chao, Y.-S.; Hsu, J. T. A.; Wu, S.-Y. Structure-Based Drug Design of a Novel Family of PPARγ Partial Agonists: Virtual Screening, X-ray Crystallography, and in Vitro/in Vivo Biological Activities. J. Med. Chem. 2006, 49, 2703-2712.
69. Oberfield, J. L.; Collins, J. L.; Holmes, C. P.; Goreham, D. M.; Cooper, J. P.; Cobb, J. E.; Lenhard, J. M.; Hull-Ryde, E. A.; Mohr, C. P.; Blanchard, S. G.; Parks, D. J.; Moore, L. B.; Lehmann, J. M.; Plunket, K.; Miller, A. B.; Milburn, M. V.; Kliewer, S. A.; Willson, T. M. A peroxisome proliferator-actiyated receptor γ ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. USA 1999, 96, 6102-6106.
70. Bruning, J. B.; Chalmers, M. J.; Prasad, S.; Busby, S. A.; Kamenecka, T. M.; He, Y.; Nettles K. W.; Griffin, P. R. Partial Agonists Activate PPARγ Using a Helix 12 Independent Mechanism. Structure 2007, 15, 1258-1271.
71. Gelman, L., Feige, J. N.; Desvergne, B. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes. Biochim. Biophys. Acta 2007, 1771, 1094-1107.
72. Gelman, L.; Michalik, L.; Desvergne, B.; Wahli, W. Kinase signaling cascades that modulate peroxisome proliferator-activated receptors. Curr. Opin. Cell Biol. 2005, 17, 216-222.
73. Miles, P. D. G.; Barak, Y.; He, W.; Evans, R. M.; Olefsky, J. M. Improved insulin-sensitivity in mice heterozygous for PPAR-γ. deficiency. J. Clin. Invest. 2000, 4 287-292.
74. Kubota, N.; Terauchi, Y.; Miki, H.; Tamemoto, H.; Yamauchi, T.; Komeda, K.; Satoh, S.; Nakano, R., Ishii, C.; Sugiyama, T.; Eto, K.; Tsubamoto, Y.; Okuno, A.; Murakami, K.; Sekihara, H.; Hasegawa, G.; Naito, M.; Toyoshima, Y.; Tanaka, S.; Shiota, K.; Kitamura, T.; Fujita, T.; Ezaki, O.; Aizawa, S.; Nagai, R.; Tobe, K.; Kimura, S.; Kadowaki, T. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 1999, 4, 597-609.
75. Miles, P. D. G.; Barak, Y.; Evans, R. M.; Olefsky, J. M. Effect of heterozygous PPARγ deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding. Am. J. Physiol. 2003, 284, E618-E626.
76. Knouff, C.; Auwerx, J. Peroxisome proliferator-activated receptor-γ calls for activation in moderation: Lessons from genetics and pharmacology. Endocr. Rev. 2004, 25, 899-918.
77. Rocchi, S.; Picard, F.; Vamecq, J.; Gelman, L.; Potier, N.; Zeyer, D.; Dubuquoy, L.; Bac, P.; Champy, M. F.; Plunket, K. D.; Leesnitzer, L. M.; Blanchard, S. G.; Desreumaux, P.; Moras, D.; Renaud, J. P.; Auwerx, J. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell 2001, 8, 737-747
78. Layman, D. K.; Walker, D. A. Potential importance of leucine in treatment of obesity and the metabolic syndrome. J. Nutr. 2006, 136, 319S-323S.
79. van Loon, L. J. C. Amino acids as pharmaco-nutrients for the treatment of type 2 diabetes. Immunol., Endocr. Metab. Agents Med. Chem. 2007, 7, 39-48.
80. Aronow, W. S.; Vicario, M. D.; Moorthy, K.; King, J.; Vawter, M.; Papageorges, N. P. Long-term efficacy of halofenate on serum triglyceride levels. Curr. Ther. Res. Clin. Exp. 1975, 18, 855-861.
81. Allen, T.; Zhang, F.; Moodie, S. A.; Clemens, L. E.; Smith, A.; Gregoire, F.; Bell, A.; Muscat, G. E. O.; Gustafson, T. A. Halofenate is a selective peroxisome proliferator-activated receptor γ modulator with antidiabetic activity. Diabetes 2006, 55, 2523-2533.
82. Minoura, H.; Takeshita, S.; Ita, M.; Hirosumi, J.; Mabuchi, M.; Kawamura, I.; Nakajima, S.; Nakayama, O.; Kayakiri, H.; Oku, T.; Ohkubo-Suzuki, A.; Fukagawa, M.; Kojo, H.; Hanioka, K.; Yamasaki, N.; Imoto, T.; Kobayashi, Y.; Mutoh, S. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. Eur. J. Pharmacol. 2004, 494, 273-281.
83. Fujimura, T.; Sakuma, H.; Ohkubo-Suzuki, A.; Aramori, I.; Mutoh, S. Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor γ. Biol. Pharm. Bull. 2006, 29, 423-429.
84. Fujimura, T.; Kimura, C.; Oe, T.; Takata, Y.; Sakuma, H.; Aramori, I.; Mutoh, S. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties. J. Pharmacol. Exp. Ther. 2006, 318, 863-871.
85. Handschin, C.; Spiegelman, B. M. Peroxisome proliferator-activated receptor γ coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr. Rev. 2006, 27, 728-735.
86. Patti, M. E.; Butte, A. J.; Crunkhorn, S.; Cusi, K.; Berria, R.; Kashyap, S.; Miyazaki, Y.; Kohane, I.; Costello, M.; Saccone, R.; Landaker, E. J.; Goldfine, A. B.; Mun, E.; DeFronzo, R.; Finlayson, J.; Kahn, C. R.; Mandarino, L. J. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc. Natl. Acad. Sci. USA 2003, 100, 8466-9471.
87. Misra, P.; Chakrabarti, R.; Vikramadithyan, R. K.; Bolusu, G.; Juluri, S.; Hiriyan, J.; Gershome, C.; Rajjak, A.; Kashireddy, P.; Yu, S.; Surapureda S.; Qi, C.; Zhu, Y.-J.; Rao, M. S.; Reddy, J. K.; Ramanujam, R. PAT5A: A partial agonist of peroxisome proliferator-activated receptor γ is a potent antidiabetic thiazolidinedione yet weakly adipogenic. J. Pharmacol. Exp. Ther. 2003, 306, 763-771.
88. Vikramadithyan, R. K.; Chakrabarti, R.; Misra, P.; Premkumar, M.; Kumar, S. K. B.; Rao, C. S.; Ghosh, A.; Reddy, K. N.; Uma, C.; Rajagopalan, R. Euglycemic and hypolipidemic activity of PAT5A: A unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity. Metab., Clin. Exp. 2000, 49, 1417-1424.
89. Berger, J. P.; Petro, A. E.; Macnaul, K. L.; Kelly, L. J.; Zhang, B. B.; Richards, K.; Elbrecht; A.; Johnson, B. A.; Zhou, G.; Doebber, T. W.; Biswas, C.; Parikh, M.; Sharma, N.; Tanen, M. R.; Thompson, G. M.; Ventre, J.; Adams, A. D.; Mosley, R.; Surwit, R. S.; Moller, D. E. Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator. Mol. Endocrinol. 2003, 17, 662-676.
90. Acton, J. J., 3rd; Black, R. M.; Jones, A. B.; Moller, D. E.; Colwell, L.; Doebber, T. W.; Macnaul, K. L.; Berger, J.; Wood, H. B. Benzoyl 2-methyl indoles as selective PPARγ modulators. Bioorg. Med. Chem. Lett. 2005, 15, 357-362.
91. Liu, K.; Black, R. M.; Acton, J. J., 3rd; Mosley, R.; Debenham, S.; Abola, R.; Yang, M.; Tschirret-Guth, R.; Colwell, L.; Liu, C.; Wu, M.; Wang, C. F.; MacNaul, K. L.; McCann, M. E.; Moller, D. E.; Berger, J. P.; Meinke, P. T.; Jones, A. B.; Wood, H. B. Selective PPARγ modulators with improved pharmacological profiles. Bioorg. Med. Chem. Lett. 2005, 15, 2437-2440.
92. Dropinski, J. F.; Akiyama, T.; Einstein, M.; Habulihaz, B.; Doebber, T.; Berger, J. P.; Meinke, P. T.; Shi, G. Q. Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARγ partial agonists. Bioorg. Med. Chem. Lett. 2005, 15, 5035-5038.
93. Kim, K. R.; Lee, J. H.; Kim, S. J.; Rhee, S. D.; Jung, W. H.; Yang, S.-D.; Kim, S. S.; Ahn, J. H.; Cheon, H. G. KR-62980: A novel peroxisome proliferator-activated receptor γ agonist with weak adipogenic effects. Biochem. Pharmacol. 2006, 72, 446-454
94. Blanc-Delmas, E.; Lebegue, N.; Wallez, V.; Leclerc, V.; Yous, S.; Carato, P.; Farce, A.; Bennejean, C.; Renard, P.; Caignard, D.-H.; Audinot-Bouchez, V.; Chomarat, P.; Boutin, J.; Hennuyer, N.; Louche, K.; Carmona, M. C.; Staels, B.; Penicaud, L.; Casteilla, L.; Lonchampt, M.; Dacquet, C.; Chavatte, P.; Berthelot, P.; Lesieur, D. Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARγ agonists. Bioorg. Med. Chem. 2006, 14, 7377-7391.
95. Carmona, M. C.; Louche, K.; Lefebvre, B.; Pilon, A.; Hennuyer, N.; Audinot-Bouchez, V.; Fievet, C.; Torpier, G.; Formstecher, P.; Renard, P.; Lefebvre, P.; Dacquet, C.; Staels, B.; Casteilla, L.; Penicaud, L. S 26948: A new specific peroxisome proliferator activated receptor γ modulator with potent antidiabetes and antiatherogenic effects. Diabetes 2007, 56, 2797-2808.
96. Savkur, R. S.; Miller, A. R. Investigational PPAR-γ agonists for the treatment of type 2 diabetes. Expert Opin. Invest. Drugs 2006, 15, 763-778.
97. Kersey, K.; Floren, L. C.; Pendleton, B.; Stempien, M. J.; Buchanan, J.; Dunn, F. T0903131, a Selective Modulator of PPAR-γ Activity, Increases Adiponectin Levels in Healthy Subjects. Diabetes 2004, 53, 656-P.
98. Picard, F.; Gehin, M.; Annicotte, J.-S.; Rocchi, S.; Champy, M.-F.; O'Malley, B. W.; Chambon, P.; Auwerx, J. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 2002, 111, 931-941.
99. Xu, J.; Liao, L.; Ning, G.; Yoshida-Komiya, H.; Deng, C.; O'Malley, B. W. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc. Natl. Acad. Sci. USA 2000, 97, 6379-6384.
100. Wang, Z.; Qi, C.; Krones, A.; Woodring, P.; Zhu, X.; Reddy, J. K.; Evans, R. M.; Rosenfeld, M. G.; Hunter, T. Critical roles of the p160 transcriptional coactivators p/CIP and SRC-1 in energy balance. Cell Metab. 2006, 3, 111-122.
101. Landles, C.; Chalk, S.; Steel, J. H.; Rosewell, I.; Spencer-Dene, B.; Lalani, E.-N.; Parker, M. G. The thyroid hormone receptor-associated protein TRAP220 is required at distinct embryonic stages in placental, cardiac, and hepatic development. Mol. Endocrinol. 2003, 17, 2418-2435.
102. Ge, K.; Guermah, M.; Yuan, C.-X.; Ito, M.; Wallberg, A. E.; Spiegelman, B. M.; Roeder, R. G. Transcription coactivator TRAP220 is required for PPARγ2-stimulated adipogenesis. Nature 2002, 417, 563-567.
103. Yamauchi, T.; Oike, Y.; Kamon, J.; Waki, H.; Komeda, K.; Tsuchida, A.; Date, Y.; Li, M.-X.; Miki, H.; Akanuma, Y.; Nagai, R.; Kimura, S.; Saheki, T.; Nakazato, M.; Naitoh, T.; Yamamura, K.; Kadowaki, T. Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat. Genet. 2002, 30, 221- 26.
104. Reginato, M. J.; Bailey, S. T.; Krakow, S. L.; Minami, C.; Ishii, S.; Tanaka, H.; Lazar, M. A. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. J. Biol. Chem. 1998, 273, 32679-32684
105. Sorbera, L. A.; Castaner, J.; Del Fresno, M.; Silvestre, J. Netoglitazone. Drugs Future 2002, 27, 132-139.
106. Lazarenko, O. P.; Rzonca, S. O.; Suva, L. J.; Lecka-Czernik, B. Netoglitazone is a PPAR-γ ligand with selective effects on bone and fat. Bone 2006, 38, 74-84.
107. Shi, G. Q.; Dropinski, J. F.; McKeever, B. M.; Xu, S.; Becker, J. W.; Berger, J. P.; MacNaul, K. L.; Elbrecht A.; Zhou, G.; Doebber, T. W.; Wang, P.; Chao, Y.-S.; Forrest, M.; Heck, J. V.; Moller, D. E.; Jones, A. B. Design and Synthesis of a-Aryloxyphenylacetic Acid Derivatives: A Novel Class of PPARα/γ Dual Agonists with Potent Antihyperglycemic aud Lipid Modulating Activity. J. Med. Chem. 2005, 48, 4457-4468.
108. Reifel-Miller, A.; Otto, K.; Hawkins, E.; Barr, R.; Bensch, W. R.; Bull, C.; Dana, S.; Klausing, K.; Martin, J.-A.; Rafaeloff-Phail, R.; Rafizadeh-Montrose, C.; Rhodes, G.; Robey, R.; Rojo, I.; Rungta, D.; Snyder, D.; Wilbur, K.; Zhang, T.; Zink R.; Warshawsky, A.; Brozinick, J. T. A peroxisome proliferator-activated receptor α/γ dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Mol. Endocrinol. 2005, 19, 1593-1605.
109. Pettersson, I.; Ebdrup, K.; Havranek, M.; Pihera, P.; Korinek, M.; Mogensen, J. P.; Jeppesen, C. B.; Johansson, E.; Sauerberg, P. Design of a partial PPARδ agonist. Bioorg. Med Chem. Lett. 2007, 17, 4625-4629.
110. Sauerberg, P., Olsen, G. S.; Jeppesen, L.; Mogensen, J. P.; Pettersson, I.; Jeppesen, C. B.; Daugaard, J. R.; Galsgaard, E. D.; Yuddal, L.; Fleckner, J.; Panajotova, V.; Polivka, Z.; Pihera, P.; Havranek, M.; Wulff, E. M. Identification and Synthesis of a Novel Selective Partial PPARδ Agonist with Full Efficacy on Lipid Metabolism In Vitro and In Vivo. J. Med. Chem. 2007, 50, 1495-1503.
111. Benson, S. C.; Pershadsingh, H. A.; Ho, C. I.; Chittiboyina, A.; Desai, P.; Pravenec, M.; Qi N.; Wang, J.; Avery, M. A.; Kurtz, T. W. Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ-Modulating Activity. Hypertension 2004, 43, 993-1002.
112. Schupp, M.; Clemenz, M.; Gineste, R.; Witt, H.; Janke, J.; Helleboid, S.; Hennuyer, N.; Ruiz, P.; Unger, T.; Staels, B.; Kintscher, U. Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 2005, 54, 3442-3452.
113. Vitale, C.; Mercuro, G.; Castiglioni, C.; Cornoldi, A.; Tulli, A.; Fini, M.; Volterrani, M.; Rosano, G. M. C. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovirsc. Diabetol. 2005, 4, No pp. given.
114. Derosa, G.; Ragonesi, P. D.; Mugellini, A.; Ciccarelli, L.; Fogari, R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: A randomized, double-blind, placebo-controlled 12-month study. Hypertens. Res. 2004, 27, 457- 64.
115. Gampe, R. T., Jr.; Montana, V. G.; Lambert, M. H.; Miller, A. B.; Bledsoe, R. K.; Milburn, M. V.; Kliewer, S. A.; Willson, T. M.; Xu, H. E. Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 2000, 5, 545-555.
116. Lambert, M. H. Docking conformationally flexible molecules into protein binding sites. In Practical Application of Computer-Aided Drug Design, Charifson, P. S., Ed., Marcel Dekker: 1997, 243-303.